Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OM336 in Sjogren's Disease and Idiopathic Inflammatory Myopathy
NCT07229144Phase 1Recruiting
- Sponsor
- Ouro Medicines
- Start
- Oct 2025
- Primary completion
- Jun 2027
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of gamgertamig in Sjögren's syndrome and idiopathic inflammatory myopathy (IIM), sponsored by Ouro Medicines. Primary endpoint: Safety and Tolerability at 12 weeks. Started Oct 2025; status: recruiting.
02
Drugs
gamgertamig
03
Conditions
Sjögren's syndromeidiopathic inflammatory myopathy (IIM)
Beyond the preview
Go deeper on NCT07229144.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07229144.